Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The consistent outperformance in multiple forms of administration against multiple existing standards of care is certainly very bullish for Summit, whose stock is nearly all the way back to an ...

Summit Therapeutics PLC (SMMT) closed the last trading session at $28.02, gaining 61.8% over the past four weeks, but there ...

Q1 2025 Earnings Call Transcript May 2, 2025 Operator: Thank you for standing by. Hello and welcome to the Summit Therapeutics Q1 2025 Earnings Conference Call. I would now like to turn the call over ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of ...

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other best cancer stocks to invest in for long-term gain. After cardiovascular disease ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% ...

Summit Therapeutics (NASDAQ: SMMT) has more than just a potential blockbuster cancer drug in its portfolio. Ivonescimab could be one of the best drugs to ever hit the market. This has investors ...